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University of Oxford, Oxford, United Kingdomi
The declining efficacy of artemisinin derivatives against Plasmodium falciparum highlights the urgent need to identify alterna-
tive highly potent compounds for the treatment of malaria. In Papua Indonesia, where multidrug resistance has been docu-
mented against both P. falciparum and P. vivaxmalaria, comparative ex vivo antimalarial activity against Plasmodium isolates
was assessed for the artemisinin derivatives artesunate (AS) and dihydroartemisinin (DHA), the synthetic peroxides OZ277 and
OZ439, the semisynthetic 10-alkylaminoartemisinin derivatives artemisone and artemiside, and the conventional antimalarial
drugs chloroquine (CQ), amodiaquine (AQ), and piperaquine (PIP). Ex vivo drug susceptibility was assessed in 46 field isolates
(25 P. falciparum and 21 P. vivax). The novel endoperoxide compounds exhibited potent ex vivo activity against both species,
but significant differences in intrinsic activity were observed. Compared to AS and its active metabolite DHA, all the novel com-
pounds showed lower or equal 50% inhibitory concentrations (IC50s) in both species (median IC50s between 1.9 and 3.6 nM in P.
falciparum and 0.7 and 4.6 nM in P. vivax). The antiplasmodial activity of novel endoperoxides showed different cross-suscepti-
bility patterns in the two Plasmodium species: whereas their ex vivo activity correlated positively with CQ, PIP, AS, and DHA in
P. falciparum, the same was not apparent in P. vivax. The current study demonstrates for the first time potent activity of novel
endoperoxides against drug-resistant P. vivax. The high activity against drug-resistant strains of both Plasmodium species con-
firms these compounds to be promising candidates for future artemisinin-based combination therapy (ACT) regimens in re-
gions of coendemicity.
Approximately 3.3 billion people (i.e., almost 50% of theworld’s population) are at risk of malaria with two Plasmo-
dium species responsible for the majority of infections: P. falcipa-
rum and P. vivax (6, 7, 43). Traditionally, malaria control and
research efforts have focused on P. falciparum, the dominant spe-
cies in Africa. However, outside Africa, P. falciparum almost in-
variably coexists with P. vivax (7), with both species inflicting
significant morbidity, particularly in infants and pregnant women
(18, 27).
Chloroquine (CQ)-resistantP. falciparum is already well estab-
lished, with emerging evidence that susceptibility to CQ inP. vivax
is also declining across much of the world in which vivax is en-
demic. This combined threat is driving the investigation of alter-
native schizonticidal treatment regimens, such as artemisinin-
based combination therapy (ACT), for deployment against both
P. falciparum and P. vivax (29). ACTs have become the mainstay
of antimalarial chemotherapy, adopted in more than 100 coun-
tries worldwide (42). This huge demand for artemisinin and its
derivatives relies on isolation from the plant source Artemisia an-
nua and is vulnerable to harvest and production costs and inter-
mittent supply (2, 11). Of particular concern are recent reports of
prolonged in vivo parasite clearance times following ACTs on the
Thai-Cambodian border (4, 21), highlighting the possibility of
emerging artemisinin resistance. These constraints have driven
new efforts to develop novel semisynthetic artemisinins or fully
synthetic peroxides, some of which are currently in phase I and II
clinical trials. The fully synthetic peroxides include the 1,2,4-tri-
oxolanes OZ277 and OZ439 (also known as ozonides) (3), and the
semisynthetic artemisinins include the 10-alkylamino-artemis-
inin derivative artemisone and its thiomorpholine precursor, ar-
temiside (8). OZ277 (also known as RBx11160 or arterolane) was
the first ozonide to enter clinical trials, is currently evaluated in
combination with piperaquine (PIP) (25), and has obtained ap-
proval for use in India. The novel ozonide OZ439 has a slower
elimination than OZ277 and is able to cure Plasmodium berghei
infections in mice with a single oral administration (3). Artemi-
sone in combination with mefloquine, amodiaquine, or clinda-
mycin cures P. falciparum infections in Aotus monkeys (24) and is
effective against murine cerebral malaria (38). Preliminary phase
II data demonstrated that artemisone is curative at one-third the
dose level of artesunate (AS) when used in patients with nonsevere
malaria (19).
Outside Africa, the high levels of malaria coendemicity and the
emergence of multidrug resistance in both species have led to calls
for a unified policy of ACT for both P. falciparum and P. vivax (5),
an approach now endorsed by Indonesia, Papua New Guinea, the
Solomon Islands, and Vanuatu. The success of such a policy is
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dependent upon confirmation of antimalarial activity of estab-
lished and novel endoperoxide drugs against clinical isolates of
both P. falciparum and P. vivax, particularly in areas of known
multidrug resistance. The aim of the current study was to in-
vestigate the ex vivo drug susceptibility profiles of novel endo-
peroxide agents and compare these with those of established
antimalarials.
MATERIALS AND METHODS
Compounds. The antimalarial drugs chloroquine (CQ), amodiaquine
(AQ; Sigma-Aldrich, Australia), piperaquine (PIP; Ranbaxy Lab. Ltd.,
Gurgaon, India), artesunate (AS; Guilin Pharmaceutical Co., Ltd.,
Guangxi, China), and dihydroartemisinin (DHA; Chongqing Holley
Wuling Mountain Pharmaceutical Co., Ltd., China) and the experi-
mental compounds OZ277, OZ439 (MMV), artemisone, and artemi-
side (The Hong Kong University of Science and Technology) were
prepared as 10 mM stock solutions in dimethyl sulfoxide (DMSO).
Drug plates were then predosed by diluting the compounds in 50%
ethanol, followed by lyophilization, and stored at 4°C. Drug plates
were quality controlled by assessing drug response profiles in the CQ-
resistant and -sensitive laboratory strains K1 and FC27, respectively,
before and after completion of the study.
Field location and sample collection. Plasmodium species isolates
were collected from patients with malaria attending outpatient clinics in
Timika, Papua Province, Indonesia, a region where multidrug-resistant
strains of P. vivax and P. falciparum are highly prevalent (10, 30, 31).
Patients with symptomatic malaria were recruited into the study if they
were singly infected withP. falciparum orP. vivax and had a parasitemia of
between 2,000l1 and 80,000l1. After written informed consent was
obtained, venous blood (5 ml) was collected by venipuncture. Host white
blood cells (WBC) were removed by using CF 11 cellulose, and packed
infected red blood cells (IRBC) were used for the ex vivo drug susceptibil-
ity assay.
Ex vivo drug susceptibility assay. Plasmodium drug susceptibility was
measured using a protocol modified from the WHO microtest as de-
scribed previously (17, 31). Two hundred microliters of a 2% hematocrit
blood medium mixture (BMM), consisting of RPMI 1640 medium plus
10% ABhuman serum (P. falciparum) or McCoy’s 5A medium plus 20%
AB human serum (P. vivax), was added to each well of predosed drug
plates containing 11 serial concentrations (2-fold dilutions) of the anti-
malarials (maximum concentration shown in parentheses) CQ (2,992
nM), AQ (80 nM), PIP (769 nM), AS (25 nM), DHA (34 nM), OZ277 (34
nM), OZ439 (34 nM), artemisone (24 nM), and artemiside (26 nM). A
candle jar was used to mature the parasites at 37.0°C for 32 to 56 h.
Incubation was stopped when 40% of ring stage parasites had reached
the mature schizont stage (i.e., 4 distinct nuclei per parasite) in the
drug-free control well.
Thick blood films made from each well were stained with 5% Giemsa
solution for 30 min and examined microscopically. The number of schi-
zonts per 200 asexual stage parasites was determined for each drug con-
centration and normalized to that of the control well. The dose-response
data were analyzed using nonlinear regression analysis (WinNonLn 4.1;
Pharsight Corporation), and the 50% inhibitory concentration (IC50) was
derived using an inhibitory sigmoid maximum effect (Emax) model. IC50
TABLE 1 Baseline characteristics of isolates for which the ex vivo assay was accomplished
Baseline characteristic P. falciparum P. vivax
No. of isolates reaching harvest/total no. of isolates (%) 23/25 (92) 18/21 (90)
Median (range) delay from venipuncture to start of culture (min) 140 (80–246) 102.5 (77–180)
Median (range) duration of assay (h) 46 (32–56) 47 (41–48)
Geometric mean (95% CIa) parasitemia (asexual parasites/l) 17,291 (11,212–26,666) 11,110 (6,925–17,823)
Median initial % (range) of parasites at ring stage 100 (100–100) 85 (59–97)
Mean (95% CI) schizont count at harvest 36 (16–80) 34 (20–50)
a CI, confidence interval.
TABLE 2 Overall ex vivo sensitivity for each drug according to the species tested
Drug
Indicated values for each group of isolates
Median IC50 (nM) in
each P. falciparum lab
linea P. falciparum clinical field isolates P. vivax clinical field isolates
FC27 (CQs) K1 (CQr) n (%)c Median IC50 (range) in nM and P value
b n (%)c Median IC50 (range) in nM and P value
b
Chloroquine 39.9 168.7 23 (100) 91.4 (37.3–147.7) 18 (100)d 48.3 (12.9–143.4)
Amodiaquine 36.2 21.7 23 (100) 11.8 (5.6–22.8) 18 (100) 15.9 (7.1–25.8)
Piperaquine 64.2 50.2 23 (100) 16.4 (4.0–43.6) 18 (100) 14.6 (4.0–28.9)
Artesunate 15.4 10.3 22 (96)e 4.5 (0.3–9.8) 15 (83)e 4.0 (1.6–6.3)
DHA 10.0 9.6 22 (96)f 6.4 (2.2–11.1), P 0.013 16 (89)e 4.9 (2.8–11.5), P 0.013
OZ277 10.9 20.0 23 (100) 3.6 (0.1–18.3), P 0.884 16 (89)e 4.6 (1.7–16.3), P 0.088
OZ439 11.1 18.6 23 (100) 2.1 (0.4–10.5), P 0.012 16 (89)e 4.5 (1.3–10.3), P 0.306
Artemisone 1.9 2.0 22 (96)e 1.9 (0.1–5.7), P 0.001 15 (83)e 0.7 (0.3–4.1), P 0.001
Artemiside 4.0 4.3 22 (96)e 2.5 (0.2–15.0), P 0.592 15 (83)e 3.0 (0.5–14.4), P 0.460
a Mean IC50s (derived from 2 independent experiments) were assessed by in vitro schizont maturation quantified by microscopy. CQ
s, chloroquine-sensitive laboratory strain; CQr,
chloroquine-resistant laboratory strain.
b P values are from a comparison with values for artesunate (Wilcoxon signed-rank test).
c Total number of assays with acceptable IC50s (percentage of samples which fulfilled the criteria for a successful culture).
d One P. vivax isolate was excluded from analysis (harvested at30 h).
e Insufficient BMM mixture to test all compounds in 3 P. vivax isolates and 1 P. falciparum isolate.
f No IC50 estimate of DHA for 1 P. falciparum isolate (highly sensitive, model not possible).
P. vivax Ex Vivo Drug Susceptibility to Artemisinins
October 2012 Volume 56 Number 10 aac.asm.org 5259
 o
n
 February 9, 2014 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
ex vivo data were used from predicted curves only where the Emax and E0
were within 15% of 100 and 0, respectively.
Data analysis. Analysis was performed using STATA software (ver-
sion 10.1; Stata Corp., College Station, TX). The Mann-Whitney U test,
Wilcoxon signed-rank test, and Spearman rank correlation were used for
nonparametric comparisons and correlations. Since previous studies have
highlighted several potential confounders of ex vivo/in vitro assessment of
drug susceptibility (13, 31), we used robust multiple regression analysis
on log-transformed data to control for the effect of potential confounders
on ex vivo drug response, including the initial parasitemia, the proportion
of parasites at ring stage at the start of the assay, and the duration of the
assay.
Ethical approval. Ethical approval for this project was obtained from
the Human Research Ethics Committee of the Northern Territory De-
partment of Health & Families and Menzies School of Health Research
(HREC 2010-1396), Darwin, Australia, and the Eijkman Institute Re-
search Ethics Commission (EIREC-47), Jakarta, Indonesia, in September
2010.
RESULTS
Antimalarial susceptibility. Ex vivo drug susceptibility was as-
sessed in field isolates from 46 patients presenting with single-
species infections of P. falciparum (n  25) or P. vivax (n  21).
Adequate growth for harvest was achieved in 92% (23/25) of P.
falciparum and 90% (19/21) of P. vivax isolates. Baseline charac-
teristics of the isolates processed are presented in Table 1. Median
IC50s for all isolates which fulfilled criteria for successful culture
for the two species and for the P. falciparum laboratory strains
FC27 and K1 are depicted in Table 2.
Drug susceptibility to CQ was significantly lower in P. falcipa-
rum isolates (median IC50, 91.4 nM; range, 37.3 to 147.7 nM) than
inP. vivax isolates (median, 48.3 nM; range, 12.9 to 143.4 nM; P
0.001) (Fig. 1), whereas OZ439 exhibited higher IC50s for P. vivax
(4.5 nM versus 2.1 nM; P 0.013) (Fig. 1). Previous studies have
highlighted a difference in the stage-specific activities of CQ and
AQ in P. vivax. Stratified analysis of P. vivax isolates with 80%
and 60 to 80% of parasites at ring stage at the start of the assay
showed a slight but significant difference in activity for AS (me-
dian IC50 of 3.5 nM in isolates with 80% rings and 4.9 nM in
isolates with 60 to 80% rings; P 0.037) and DHA (median IC50
of 4.8 nM in isolates with80% rings and 6.0 nM in isolates with
60 to 80% rings; P 0.051) but no stage-specific difference in ex
vivo susceptibility to the other compounds (Table 3).
A within-species comparison with AS revealed significantly
lower IC50s for artemisone in both species (median AS IC50 of 4.5
nM versus a median artemisone IC50 of 1.9 nM [P 0.001] for P.
falciparum and 4.0 nM versus 0.7 nM, respectively [P 0.001], for
P. vivax). The median IC50 for OZ439 was also significantly lower
than that for AS, but this was apparent only in P. falciparum
isolates (median, 2.1 nM; P  0.012). IC50s for DHA were
significantly higher than those for AS in both species (median
DHA IC50 of 6.4 nM [P  0.013] for P. falciparum and 4.9 nM
[P 0.013] for P. vivax) (Table 2). The trends in drug suscep-
tibility compared to the AS reference drug remained after con-
trolling for the initial stage composition of the parasite at the
start of the assay.
Cross-susceptibility patterns. Cross-susceptibility patterns
were assessed using the Spearman correlation analysis (Table 4).
The initial parasitemia was identified as a weak confounding fac-
tor for the ex vivo drug response to OZ277 in both species (P.
falciparum, rs 0.568, P 0.021; P. vivax, rs 0.394, P 0.036)
and artemisone and artemiside in P. vivax (rs 0.617, P 0.005,
and rs  0.481, P  0.035, respectively), whereas this was not
apparent for either the duration of assay or the initial parasite
stage. In multivariate analysis, correlation patterns did not
change substantially after controlling for these confounding
FIG 1 Ex vivo drug susceptibility (median IC50s) of the synthetic ozonides
OZ277 and OZ439 and the semisynthetic endoperoxides artemisone and ar-
temiside in P. falciparum (filled symbols) and P. vivax (open symbols) clinical
field isolates.
TABLE 3 Overall ex vivo sensitivity for P. vivax with80% and80% of parasites at ring stage at the start of the assay
Drug
Indicated values for P. vivax isolates with:
80% rings 60–80% rings
n (%)a Median IC50 (range) in nM and P value
b n (%)a Median IC50 (range) in nM and P value
b
Chloroquine 11/11 (100) 45.7 (12.9–143.4) 7/7 (100) 50.8 (23.6–68.6)
Amodiaquine 11/11 (100) 17.1 (7.1–25.8) 7/7 (100) 13.4 (7.5–17.0)
Piperaquine 11/11 (100) 13.1 (4.0–28.7) 7/7 (100) 21.9 (5.2–28.9)
Artesunate 10/11 (91) 3.5 (1.6–6.2) 5/7 (71) 4.9 (3.6–6.3)
DHA 10/11 (91) 4.8 (2.8–6.8), P 0.029 6/7 (86) 6.0 (4.3–11.5), P 0.225
OZ277 10/11 (91) 5.2 (1.7–8.7), P 0.037 6/7 (86) 4.0 (1.8–16.3), P 0.500
OZ439 10/11 (91) 3.7 (1.3–8.8), P 0.285 6/7 (86) 4.8 (2.6–10.3), P 0.892
Artemisone 10/11 (91) 0.6 (0.3–3.4), P 0.005 5/7 (71) 0.9 (0.6–4.1), P 0.043
Artemiside 10/11 (91) 2.8 (0.7–14.4), P 0.386 5/7 (71) 2.9 (0.5–13.3), P 0.893
a Total number of assays with acceptable IC50s/total number of assays (percentage).
b P values are from a comparison with values for artesunate (Wilcoxon signed-rank test).
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factors (Table 4), but there was a difference in correlation pat-
terns between the two Plasmodium species. In P. falciparum
isolates, novel endoperoxide drug responses correlated signif-
icantly with those of AS, DHA, CQ, and PIP. While ex vivo drug
response was correlated with the novel endoperoxides (ozo-
nides and artemisone and artemiside) in P. vivax isolates, there
was no correlation between these compounds and AS, DHA
(the exception being artemiside), CQ, or PIP in this species
(Table 4).
DISCUSSION
The synthetic peroxides OZ277 and OZ439 and the semisynthetic
10-alkylamino-artemisinin derivatives artemisone and artemiside
demonstrate potent ex vivo activity against both Plasmodium spe-
cies. All of the novel compounds tested in our study showed IC50s
lower than or equal to those of AS and DHA, with IC50s varying
between 1.9 and 3.6 nM against P. falciparum and 0.7 and 4.6 nM
in P. vivax (Table 2).
Significant interspecies differences in ex vivo drug responses
were observed for CQ (the median CQ IC50 is greater in P. falcip-
arum than P. vivax) and OZ439 (the median OZ439 IC50 is greater
in P. vivax than P. falciparum). The differences observed in CQ
IC50s may reflect the spectrum of acquired resistance for each
species prevalent within the community, but this is unlikely to
explain the difference for OZ439. Although intrinsic species vari-
ation in life cycle maturation and drug susceptibility inherent to
the assay cannot be ruled out, the number of isolates assessed was
relatively small, with a borderline level of significance for the
OZ439 comparison (P 0.013), and thus the result may represent
a chance occurrence within the context of multiple comparisons.
A comparative analysis in P. vivax between isolates with80%
rings and 60 to 80% rings at the start of the assay revealed a sig-
nificant, albeit modest, difference in IC50s for AS and DHA, with
isolates containing 80% rings at the start of the assay appearing
more susceptible. Stage specificity of drug action in P. vivax has
been highlighted in previous studies for CQ (31, 33) in which ex
vivo susceptibility increased by more than 20-fold for isolates pre-
dominantly at the trophozoite stage compared to the ring stage.
The variation in drug susceptibility between parasites at the ring
and trophozoite stages was considerably less for AS and DHA
(1.5-fold) and was not apparent for any of the novel endoperoxide
compounds (Table 2).
The IC50 values for DHA were significantly higher than those
for artesunate and, to various degrees, the other endoperoxides.
This may represent either reduced stability of DHA in predosed
drug plates (35) or differences in in vitro drug partition and me-
tabolism (14, 16, 37). High variability and fluctuations in IC50s for
artemisinin and its derivatives have been reported for both P. fal-
ciparum laboratory strains and field isolates (15, 34, 41) and re-
flect, at least in part, the application of nonstandardized in vitro
assay systems, including differences in levels of parasitemia at the
start of the assay, parasite synchrony, duration of the assay, and
quantification method of the drug response (9, 12, 13). These
variations were also apparent in the IC50 estimates derived from
laboratory-adapted P. falciparum strains in the current study, for
which drug susceptibility was assessed by the schizont maturation
test as opposed to a reinvasion assay. The median IC50s ranged
from 1.9 to 15.4 nM and 2.0 to 20.0 nM in the CQ-sensitive and
CQ-resistant P. falciparum culture-adapted strains FC27 and K1,
respectively (Table 2).
The schizont maturation test has been used to quantify P. fal-
ciparum drug susceptibility for more than 30 years, although al-
ternative, more robust methods are now widely used (1a). How-
ever, for P. vivax, the assay options remain limited, and in view of
the marked stage specificity of drug action, microscopic quantifi-
cation of parasite growth remains the preferred option (12a, 17,
31). Previous studies have demonstrated that IC50 estimates de-
TABLE 4 Correlation coefficients for ex vivo antimalarial susceptibilities
in P. falciparum and P. vivax field isolates
Novel drug and potential
confounder or compared
antimalarial drug
Correlation coefficient and P value for field
isolates ofa:
P. falciparum P. vivax
Coefficient P value Coefficient P value
OZ277
Parasitemia 0.568 0.021 0.394 0.036
Duration of assay 0.041 0.667 0.080 0.537
Rings at start of the assay NA NA 0.053 0.641
Chloroquine 0.736 0.032 0.050 0.176
Amodiaquine 0.397 0.181 0.059 0.546
Piperaquine 0.718 <0.001 0.027 0.057
Artesunate 0.291 0.002 0.282 0.389
DHA 0.581 0.014 0.424 0.172
OZ439 0.853 <0.001 0.456 0.325
Artemisone 0.767 <0.001 0.693 0.001
Artemiside 0.828 <0.001 0.611 0.059
OZ439
Parasitemia 0.424 0.104 0.082 0.487
Duration of assay 0.193 0.290 0.020 0.854
Rings at start of the assay NA NA 0.117 0.494
Chloroquine 0.658 0.018 0.427 0.014
Amodiaquine 0.563 <0.001 0.100 0.145
Piperaquine 0.653 0.004 0.077 0.809
Artesunate 0.486 0.019 0.629 0.091
DHA 0.665 0.008 0.353 0.054
Artemisone 0.693 <0.001 0.550 0.031
Artemiside 0.809 <0.001 0.500 0.052
Artemisone
Parasitemia 0.353 0.069 0.617 0.005
Duration of assay 0.258 0.177 0.078 0.725
Rings at start of the assay NA NA 0.268 0.504
Chloroquine 0.682 0.016 0.327 0.432
Amodiaquine 0.319 0.681 0.325 0.010
Piperaquine 0.747 <0.001 0.600 0.528
Artesunate 0.501 <0.001 0.593 0.452
DHA 0.573 <0.001 0.621 0.273
Artemiside 0.461 0.308 0.454 <0.001
Artemiside
Parasitemia 0.393 0.133 0.481 0.035
Duration of assay 0.143 0.388 0.195 0.496
Rings at start of the assay NA NA 0.156 0.596
Chloroquine 0.660 0.010 0.021 0.849
Amodiaquine 0.509 0.060 0.157 0.216
Piperaquine 0.565 0.038 0.111 0.781
Artesunate 0.273 0.143 0.489 0.028
DHA 0.570 0.055 0.711 0.012
a Correlation coefficients were obtained by the Spearman rank correlation. P values
were obtained by robust multiple regression analysis. Bold values indicate significant
correlations. NA, not applicable.
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rived from schizont maturation tend to be higher than those de-
rived by in vitro reinvasion assays with growth quantified by 3H-
hypoxanthine incorporation (1, 23, 36, 39).
Recent clinical, molecular, and in vitro studies have raised the
specter of emerging drug resistance to the artemisinin derivatives,
the focus of which appears to be on the western border of Cam-
bodia. The hallmark of artemisinin tolerance is a delayed parasite
clearance rate in vivo. However, the relationship between this de-
layed parasitological response and in vitro artemisinin drug sus-
ceptibility using established in vitro assays is unclear (4, 21, 22).
This lack of in vivo-in vitro correlates has undermined the defini-
tion of artemisinin resistance and the ex vivo characterization of
this process (20, 28, 40). As fears that artemisinin tolerance has
already spread beyond Cambodia grow, there is an urgent need to
develop ex vivo assay systems to characterize better the phenotypic
response of Plasmodium to current and novel artemisinin deriva-
tives. These will need to address stage-specific quantification of in
vitro/ex vivo drug response and potentially the detection and
quantification of dormant parasite stages.
Our study is one of the first to assess parasite susceptibility of a
range of endoperoxide compounds, quantifying stage-specific
growth between two Plasmodium species. In P. falciparum, the
activity of the novel endoperoxides correlated with that of AS,
DHA, CQ, and PIP, a phenomenon previously observed in studies
of field isolates (2a, 14, 26, 31). The same trend was observed in P.
vivax but did not reach statistical significance. Although this may
simply reflect the small number of isolates tested and, thus, the
low statistical power to detect a true difference, it may also repre-
sent species-specific differences in drug uptake and metabolism as
well as the mode of action of these compounds.
The novel endoperoxides have a number of advantages, in-
cluding better pharmacodynamic profiles, pharmacokinetic pro-
files amenable to single-dosing strategies, and feasibility of synthe-
sis, over currently used artemisinin derivatives. Our study
highlights their potent ex vivo activity against clinical field isolates
of both P. falciparum and P. vivax in an area of known multidrug
resistance. Together, these factors demonstrate that these novel
compounds represent promising candidates for future ACT com-
bination regimens that will have activity in areas of coendemicity.
Development of ex vivo assays that robustly quantify ex vivo/in
vitro growth dynamics will help to characterize the stage-specific
activity of these compounds and facilitate assessment of their ac-
tivity against clinical Plasmodium field isolates in areas in which
the clinical efficacy of artemisinin is declining.
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